14-day Premium Trial Subscription Try For FreeTry Free

TG Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 66.92. In total, the insiders bought 12 466 046 and sold 1 892 493 TGTX shares in the last 100 trades.

Insider Power

(Last 100 transactions)
66.92
Buy 12 466 046 Shares
Sell 1 892 493 Shares

Historical Insider Trades

Date Type Action Person Amount
Jun 20, 2024 Common Stock Sell Lonial Sagar 16 348
Jun 19, 2024 Common Stock Buy Lonial Sagar 22 250
Jun 19, 2024 Common Stock Buy Hume Daniel 22 250
Jun 19, 2024 Common Stock Buy Hoberman Kenneth 22 250
Jun 19, 2024 Common Stock Buy Echelard Yann 22 250
Jun 19, 2024 Common Stock Buy Charney Laurence N 22 250
Jun 17, 2024 Common Stock Sell Lonial Sagar 9 585
Mar 13, 2024 Common Stock Sell Lonial Sagar 5 000
Mar 12, 2024 Common Stock Sell Charney Laurence N 22 000
Feb 14, 2024 Buy Power Sean A 0
Jan 06, 2024 Common Stock Buy Weiss Michael S 1 001 908
Jan 05, 2024 Common Stock Sell Charney Laurence N 17 500
Jan 05, 2024 Common Stock Buy Power Sean A 75 000
Jan 03, 2024 Common Stock Sell Power Sean A 47 867
Sep 28, 2023 Common Stock Sell Lonial Sagar 20 000
Sep 28, 2023 Common Stock Buy Hume Daniel 20 000
Sep 28, 2023 Common Stock Buy Hoberman Kenneth 20 000
Sep 28, 2023 Common Stock Buy Echelard Yann 20 000
Sep 28, 2023 Common Stock Buy Charney Laurence N 20 000
Aug 11, 2023 COMMON STOCK Buy Weiss Michael S 100 000
Jun 23, 2023 COMMON STOCK Sell Lonial Sagar 34 854
Jun 02, 2023 COMMON STOCK Sell Power Sean A 73 647
Mar 12, 2023 COMMON STOCK Buy Power Sean A 85 000
Mar 12, 2023 COMMON STOCK Buy Weiss Michael S 985 000
Jan 06, 2023 Common Stock Buy Echelard Yann 9 000
Click to get the best stock tips daily for free!
ABOUT TG THERAPEUTICS
TG Therapeutics
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbra...
GOLDEN STAR
Ticker Change Signal Date
WM
$207.93
0.558% Oct 01
VET
$9.77
7.06% Sep 30
FSK
$19.73
1.57% Sep 30
XOM
$115.82
5.84% Sep 27
HES
$133.61
5.43% Sep 27

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE